Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06549335
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-08
Brief Title:
Zanubrutinib Obinutuzumab and Lenalidomide ZGR in High-risk Treatment-naive Patients with Follicular Lymphoma FL
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Efficacy and Safety of Zanubrutinib Obinutuzumab and Lenalidomide ZGR Regimen in High-risk Treatment-naive Patients with Follicular Lymphoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a prospective multiple-centers open-label single-arm clinical study designed to evaluate the efficacy and safety of Zanubrutinib Obinutuzumab and Lenalidomide ZGR in high-risk treatment-naive patients with follicular lymphomas
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None